
Matthew E Kennedy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4713965/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Design and discovery of C2-fluoroalkyl iminothiazine dioxides as BACE inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 56, 128463.	2.2	0
2	Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 11-19.	2.5	16
3	<i>Gga3</i> deletion and a <i>GGA3</i> rare variant associated with late onset Alzheimer's disease trigger BACE1 accumulation in axonal swellings. Science Translational Medicine, 2020, 12, .	12.4	11
4	Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nature Medicine, 2020, 26, 1256-1263.	30.7	262
5	LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Science Translational Medicine, 2020, 12, .	12.4	85
6	BACE1 partial deletion induces synaptic plasticity deficit in adult mice. Scientific Reports, 2019, 9, 19877.	3.3	25
7	Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. Journal of Medicinal Chemistry, 2017, 60, 2983-2992.	6.4	113
8	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage. Journal of Alzheimer's Disease, 2017, 59, 1393-1413.	2.6	24
9	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2016, 59, 10435-10450.	6.4	126
10	The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. Science Translational Medicine, 2016, 8, 363ra150.	12.4	352
11	Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates. Journal of Medicinal Chemistry, 2016, 59, 3231-3248.	6.4	36
12	MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 397-409.	2.5	234
13	Function, therapeutic potential and cell biology of <scp>BACE</scp> proteases: current status and future prospects. Journal of Neurochemistry, 2014, 130, 4-28.	3.9	269